AQUEOUS CHROMOPHORE AND/OR EFFECT-PRODUCING COATING MATERIAL, AND USE OF THE SAME

Details for Australian Patent Application No. 2003285313 (hide)

Owner BASF COATINGS AG

Inventors SAPPER, Gotz-Ekkehard; HUMMERT, Tobias

Pub. Number AU-A-2003285313

PCT Number PCT/EP2003/0123

PCT Pub. Number WO2004/053007

Priority 10257377.8 09.12.02 DE

Filing date 5 November 2003

Wipo publication date 30 June 2004

International Classifications

C09D 175/04 Coating compositions based on polyureas or polyurethanes - Polyurethanes

C08G 018/66 Polymeric products of isocyanates or isothiocyanates

C08G 018/67 Polymeric products of isocyanates or isothiocyanates

C08G 018/79 Polymeric products of isocyanates or isothiocyanates

C08F 290/14 Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups

C08G 018/08 Polymeric products of isocyanates or isothiocyanates

Event Publications

1 April 2004 Complete Application Filed

  Priority application(s): 10257377.8 09.12.02 DE

5 August 2004 Application Open to Public Inspection

  Published as AU-A-2003285313

25 August 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003285314-USE OF EDG2 RECEPTOR IN AN ANIMAL MODEL OF HEART FAILURE

2003285312-PHARMACEUTICAL COMPOSITION COMPRISING A BETA3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR